SHANGHAI, March 19, 2026 /PRNewswire/ -- D3 Bio Inc, a global clinical-stage biotechnology company focused on developing transformative oncology therapeutics, is pleased to announce that five abstracts have been accepted for presentation at the upcoming American Association for Cancer...
Hence then, the article about d3 bio to showcase its innovative kras pipeline at aacr 2026 including an oral presentation at clinical plenary session was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session )
Also on site :
- A Dead Character's Live Text, Justin Trudeau, and a Pity Party: Inside the 'Firefly' Announcement Panel
- Lea Michele Shares Why Recording ‘Nobody’s Side’ From Broadway’s ‘Chess’ Was ‘One of The Most Incredible Moments’ Of Her Career
- Ubisoft are ending game development at long-time Tom Clancy studio Red Storm with 105 staff laid off, according to reports